Bertheau reported that TP53 might be predictive for chemotherapy response in a particular setting: In a pooled analysis of 144 breast cancers from three series, this group found that pCR rates in TP53 mutant tumors strongly depended on the type of chemotherapy, and were significantly higher after high-dose cyclophosphamide (36%) as opposed to standard-dose (4%) or no cyclophosphamide (12%). This evidence concerns the gene TP53 and breast carcinoma.